Semax sped neurological recovery in open-label Russian stroke trials

What is Semax?

Semax is a synthetic heptapeptide built from ACTH(4-7), the fragment of adrenocorticotropic hormone with no hormonal, cortisol-driving activity, stabilized with a Pro-Gly-Pro tail to slow enzymatic degradation.

With the hormonal domain removed, Semax does not act as a corticosteroid signal; the interest is in what the fragment does independently in the brain.

How is Semax thought to work in the brain?

Semax's most-cited mechanism is upregulation of BDNF, brain-derived neurotrophic factor, and its receptor TrkB. In rats, a single intranasal dose produced a three-fold increase in hippocampal BDNF mRNA and a 1.4-fold increase in BDNF protein, alongside improved performance on a conditioned avoidance task ^[3].

BDNF supports synaptic plasticity and neuronal survival, a coherent story for post-injury recovery and, speculatively, for cognitive function in intact brains. Human trials in stroke patients found circulating BDNF increases that tracked with clinical improvement ^[2]. That is a real signal, but plasma BDNF in an injured, recovering brain is a different physiological situation from baseline BDNF tone in a healthy person hoping to focus better at a desk.

Dopaminergic and serotonergic modulation is also proposed, largely by extension from ACTH-fragment pharmacology and animal work. None of the studies cited below is a dedicated human dopamine-pathway study, so that part of the mechanism is plausible, not demonstrated in people.

Does Semax improve cognition in healthy adults?

No placebo-controlled trial has tested cognition as a primary endpoint for Semax in healthy adults, and the one healthy-volunteer study enrolled 20 men with no placebo arm ^[4].

That study gave intranasal Semax at 0.25-1.0 mg, roughly 4-16 mcg/kg, to two small cohorts. It reported EEG changes consistent with other nootropic agents under hypoxic challenge, plus improved "operator work efficiency" and attention sustained over 20-24 hours ^[4].

Forum content leans on this study hardest for "it works for focus." It is an interesting pilot signal, not proof: twenty people, no control group, one dose paradigm, and three decades old.

What do the Semax stroke trials show?

Semax's strongest human data come from Russian stroke trials that found faster neurological recovery, but the individual trials lacked randomization and placebo arms ^[1]⁠^[2].

A 110-patient non-randomized controlled trial found that adding Semax, at 12-18 mg/day intranasally for 5-10 days, to standard stroke therapy accelerated regression of neurological deficits compared with conventional therapy alone. That study was the primary basis for Russian regulatory approval ^[1].

A later open-label trial, also with 110 patients, used a different schedule of 6000 mcg/day in two 10-day courses. It found increased plasma BDNF alongside faster gains on the Barthel index and motor scoring, and it again lacked randomization and a placebo arm ^[2].

The one meta-analysis in this area pooled three studies (n=181) out of eight screened. It found significant NIHSS improvement at 10-14 and 21 days in moderate-to-severe stroke, plus improved mobility scores versus placebo across severity subgroups, which makes it the only source with a placebo comparison. The authors still concluded that the evidence is insufficient and that a proper multicenter double-blind trial is needed. When the people who ran the meta-analysis say the evidence is not there yet, that is the ceiling for this claim.

How strong is the evidence for Semax overall?

Semax's evidence earns grade C: a consistent directional signal, concentrated almost entirely in one research tradition, without the blinding and randomization that would rule out bias.

All four human studies share the same structural weaknesses: open-label design, no blinding, and, in three of the four, no placebo arm at all. Those gaps leave expectation effects, natural recovery trajectories, and investigator bias unexcluded.

Decades of use in Russia do not amount to clinical proof. Russian approval rested on the 110-patient open-label comparator trial ^[1], and the only meta-analysis called for a proper multicenter trial.

The signal is a research lead worth taking seriously. It is not a demonstrated cognitive-enhancement effect in healthy adults.

Is N-Acetyl Semax Amidate the same as Semax?

N-Acetyl Semax Amidate is a chemically modified version of Semax, and none of the cited human trials tested it.

Every study cited below used Semax, the original heptapeptide. Most of what peptide vendors sell to consumers as "Semax" is N-Acetyl Semax Amidate, which adds an acetyl group and an amidated C-terminus intended to improve stability and extend activity.

A modified molecule with a different degradation profile will have a different effective dose, a different time to onset, and potentially different receptor kinetics from the parent compound. No published human pharmacokinetic study compares Semax with N-Acetyl Semax Amidate, so anyone using vendor-sourced material is working from an unverified dose-equivalence assumption. For the Selank counterpart, see the evidence on N-acetyl Selank amidate.

Where does the 200 to 600 mcg Semax dose come from?

The online Semax protocol, 200 to 600 mcg in 1 to 3 daily doses cycled for 2 to 4 weeks, has no citation trail to any study cited below.

The only human dosing anchors in the cited studies are 12-18 mg/day intranasally for 5-10 days in acute stroke ^[1], 6000 mcg/day in stroke rehabilitation ^[2], and single doses of 0.25-1.0 mg (about 4-16 mcg/kg) in healthy volunteers ^[4]. These are clinical, supervised, short-course protocols in specific patient populations, using original Semax.

The forum protocol maps cleanly onto none of them and does not match the compound most people are buying. It appears to be a convention that emerged from repetition rather than data. In the worst case, applied to N-Acetyl Semax Amidate, it is a number never grounded in any human data for either compound, propagated from vendor to vendor.

Is Semax safe?

Semax side effects in the published trials are mild and largely benign: nasal irritation, headache, occasional overstimulation, and rare metallic taste.

Those data come almost entirely from short-course Russian clinical use. None of the cited studies provides long-term or non-Russian human safety data.

Semax and its analogs are unapproved research chemicals in the US and EU. Anyone acquiring them assumes sourcing and purity risk that sits entirely outside the pharmacology question, and none of the cited trials speaks to that risk. See how to read a peptide certificate of analysis.

What is still unknown about Semax?

Five specific gaps remain in the Semax evidence:

• A Western trial. No Western multicenter placebo-controlled RCT exists for Semax in any population.
• Long-term use in healthy adults. No human trial, of any design, has tested repeated or long-term intranasal dosing in healthy adults for cognitive outcomes.
• Analog equivalence. No published human pharmacokinetic study compares Semax with N-Acetyl Semax Amidate.
• Immunogenicity. No data exist on immunogenicity risk from repeated peptide exposure via the nasal mucosa over months or years.
• Chronic nasal tissue effects. No data exist on chronic intranasal tissue effects beyond the short courses studied in stroke patients.

Stack claims are a separate question, covered in the Selank and Semax stack evidence.